New solution provides 99.999% accuracy, LLM-style phrase matching, and real-time validation - at no additional cost to customers
Read More
Strategic Partnership Secures 2026 Production Scale; Breakthrough Heat-Pump Technology Eliminates Backup Heat While Maintaining High Efficiency in All Climates
Read More
A milestone that demonstrates how Roxi's AI-powered insight, delivered through Giatec SmartMix, is helping concrete producers improve quality, reduce variability, and achieve measurable cost savings at scale.
Read More
The retirement phase experts found that a startling number of Americans are financially unprepared for the next market crash and are concerned about what happens next
Read More
News Release Highlights:
Forte Group has confirmed the effective date of its previously announced corporate name change to Vanta Holdings Inc. ("VANTA") and approved a strategic 10-for-1 share consolidation, both to take effect at the start of trading on January 13, 2026, advancing the Company's corporate growth strategy and capital markets positioning.
The transition to the VANTA identity unifies the Company's Blackwater ready-to-drink platform and longevity-focused nutraceutical portfolio under a single, modernized brand, aligning the parent company and its consumer-facing product ecosystem and supporting scalable commercialization across Canadian, U.S., and international markets.
The share consolidation is intended to enhance the marketability of the Company's common shares, improve investor accessibility, and provide flexibility to support future corporate initiatives and financing activities, while aligning the Company's capital structure with its long-term operational and growth objectives.
Riflessi to Deploy Digital Twins of Luxury Fashion Lines of Brunello Cucinelli, Gucci, Tom Ford, Kiton and Tommy Hilfiger® among other Leading Brands with Interactive DVHOLO
3D Holographic Display in New York's Fifth Avenue Fashion District
Read MoreArticle discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure
Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives
Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint
New peer-reviewed data published in the scientific journal Cartilage uses the complete set of follow-up data from GelrinC's Phase II study, which establishes GelrinC as a leader in long-term durable cartilage repair, using objective, quantitative MOCART assessment to demonstrate morphologic outcomes that consistently outperform other treatment modalities
The data presented by Regentis show that two years after treatment, the repaired cartilage appears very close to normal healthy cartilage, highlighting the long-term durability of GelrinC and reinforcing its competitive superiority in the cartilage repair landscape
GelrinC is already approved in Europe and currently in a pivotal Phase III U.S. FDA study
Read MoreWith 12,000+ licenses issued, more than 100 academic partnerships, and a surge in open-source innovation, QNX Everywhere is empowering the next generation of embedded systems developers
Read More